logo
New research continues to link marijuana with schizophrenia. Experts say it's not so simple

New research continues to link marijuana with schizophrenia. Experts say it's not so simple

Yahoo14-02-2025

A study this week reported an association between people's medical records listing cannabis use disorder and both schizophrenia diagnoses and psychosis — but experts emphasized the data should not be used to draw causal conclusions about cannabis use and these risks.
In a study published in JAMA Network Open, the authors reported that the proportion of people with a new diagnosis of schizophrenia who had cannabis use disorder listed in their record increased after cannabis was legalized in Canada. The rates of nonspecified psychosis also increased during this time among people with this label in their record, said Dr. Daniel T. Myran, the lead author and a researcher at the Ottawa Hospital Research Institute.
'Seven percent of people in Canada use cannabis nearly every day, and there's now more people in the United States who use cannabis every day than drink alcohol every day,' Myran told Salon in a phone interview. 'I see this as a signal that this is something that could actually become a pretty important public health concern.'
Across the study period, the overall incidence of schizophrenia remained stable, and it has remained stable since the 1990s. The authors state that this 'occurred because the incidence of schizophrenia increased among younger individuals while decreasing in older adults" during the study period.
Yet this is important to note considering cannabis use has significantly increased in the past decade.
'If cannabis use 'causes' schizophrenia, it is absolutely impossible that the rate of schizophrenia would not be going up with the rates of cannabis use increasing 1,000-fold,' said Dr. Peter Grinspoon, a cannabis specialist at Massachusetts General Hospital.
This isn't the first time a link has been reported between cannabis and psychosis. The two have been tangled up together since the 1930s with the release of the anti-cannabis propaganda film, 'Reefer Madness,' in which children used cannabis and experienced a series of hallucinations and negative side effects.
As researchers began examining whether there was a link between cannabis use and psychosis and schizophrenia, the nuances involved in many of these experiments were lost. A 2017 report from the National Academies of Sciences, Engineering, and Medicine concluded: 'There is substantial evidence of a statistical association between cannabis use and the development of schizophrenia or other psychoses, with the highest risk among the most frequent users.'
But many assumed a causal relationship from studies like these, which were not designed to be able to determine causal relationships. An alternate hypothesis, for example, suggests the possibility that people who are prone to schizophrenia are using cannabis because it helps treat some of their symptoms.
Although some have pointed out that implying causation with this association is not possible with this kind of data, the former narrative has continued to be perpetuated in the media and scientific journals across decades.'Debates on the science of cannabis risks have always been highly politicized, characterized by subjective takes and often cherry-picked data to support different views — whether in supporting or opposing reforms like decriminalization or legalization,' said Steve Rolles, a senior policy analyst for the Transform Drug Policy Foundation. 'This problem is exemplified by the debate on cannabis and psychotic illness risks, with people able to trawl the voluminous body of research, and then amplify or ignore the findings that either support or undermine their particular position.'
High-potency cannabis with THC levels above 15% can produce psychotic states that cause paranoia and hallucinations, but this is a temporary state that does not mean people will go on to be diagnosed with schizophrenia, said Dr. Muhammad Aadil, an addiction psychiatrist at the Albert Einstein Medical School in New York. However, researchers could not measure the type of cannabis and its potency in this study.
'People are just having a bad reaction because of two reasons in my opinion,' Aadil told Salon in a phone interview. 'They don't know what they are consuming and they don't know what its effects are going to be on their body.'
Myran emphasized this was not a causal study and that there were several factors that could not be accounted for that could be confounding the results, like whether patients had a family history of mental health disorders.
In another study also published last week, his research group also reported an association between people who had been labeled as having a cannabis use disorder on their medical record and increased mortality. Similarly, many people might be using cannabis to self-medicate for underlying conditions that could explain some of those associations — in other words, sick people at risk of death may seek out marijuana — and some important potential confounding factors, like whether patients used tobacco, were not included.
Yet understanding the characteristics of these patients is crucial when making associations like this, especially because more people who were considered to have cannabis use disorder in the study had conditions like hypertension, asthma and cardiovascular disease, said Dr. Carl Hart, a researcher at Columbia University.
'That is not typically what you see in cannabis users,' Hart told Salon in a phone interview. 'I don't know who this population is, and it could be people who are just having problems, and who happen to smoke cannabis, too.'
In both studies, people were listed as having a cannabis use disorder based on whether they visited the emergency department for care related to cannabis use. However, cannabis use disorder is a diagnosis that typically requires a more detailed evaluation by a health care provider than what might be performed in an emergency department, Hart said.
That means some patients might have been classified as having cannabis use disorder when they did not, which the authors acknowledged in the study.
'A lot of people took too big of a gummy and had anxiety and went to the hospital, and they're calling that cannabis use disorder,' Grinspoon told Salon in a phone interview. 'If you just go by hospital spreadsheets it's completely misleading.'
Research on cannabis is further behind many other areas of study because it is still federally recognized as a controlled substance. And although federal funding has increased over the years for these studies, they tend to focus more on potential harms than on cannabis' therapeutic potential.
Although the Biden administration proposed moving cannabis from a Schedule I substance to Schedule III, which would remove most criminal penalties and barriers to conducting research, it has not been enacted yet. It's unclear whether the Trump administration will continue those efforts.
Regardless of whether cannabis is legal or not, people will continue to use it, and educating them about safe use has been shown to be the most effective way to reduce harm.
'Criminalization and prohibition makes doing this much more difficult,' Rolles said. 'Resources are siphoned away from proven public health measures into counterproductive enforcement, and the stigma of criminalization pushes key target populations away from the very services they could most benefit from.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dementia Risk Declining With Each Generation, Says Promising New Study
Dementia Risk Declining With Each Generation, Says Promising New Study

Yahoo

time2 hours ago

  • Yahoo

Dementia Risk Declining With Each Generation, Says Promising New Study

Dementia cases are on the rise around the world. In 2021, 57 million people were living with one of the neurodegenerative diseases under the dementia umbrella, and by 2050, that number is expected to reach 153 million. But a new study suggests the tides may be turning, with younger generations facing lower risks for the disease as they age. The research team, led by economist Xiaoxue Dou from the University of Queensland in Australia, ran a cross-sectional observational study using health survey data from the US, Europe and England: one that's representative of cross-sections of the populations involved at a single point in time, and based on observational data. The researchers only used variables that were available across all the survey data to estimate participants' dementia status, to compensate for any missing observations. "Birth cohorts born more recently were less likely to develop dementia in all three regions, albeit at different rates," the authors state in a journal article. "This decreasing trend was more pronounced among women than men." They particularly focused on people aged 71 years or older, with the data sorted into age groups spanning four years. Compared with the older groups, younger cohorts had lower age-specific dementia prevalence rates: 21.2 percent for those in the US study; 38.9 percent in the European study; and 28.3 percent in England. "For example, in the US, among people aged 81 to 85, 25.1 percent of those born between 1890-1913 had dementia, compared to 15.5 percent of those born between 1939-1943," economist and co-author Sabrina Lenzen of the University of Queensland told Nicola Davis at The Guardian. The team cautions their data may not accurately reflect what is happening in minority groups. But the findings suggest that, while aging populations globally will probably mean greater numbers of people living with dementia, the percentage of people affected may actually be decreasing, at least among the groups studied. This generational decrease in dementia risk, the study's authors write, "has important implications for health care planning, long-term care policies, and workforce requirements in aging populations." This research was published in JAMA Network Open. Several Psychiatric Disorders Share The Same Root Cause, Study Finds New Smart Dental Floss Can Detect Your Stress From Saliva Gluten Intolerance vs Celiac Disease: Experts Reveal The Key Differences

UK Valproate Restrictions in Men Justified? New Data
UK Valproate Restrictions in Men Justified? New Data

Medscape

time16 hours ago

  • Medscape

UK Valproate Restrictions in Men Justified? New Data

A large Danish cohort study showed no significant increase in neurodevelopmental disorders (NDDs) among children fathered by men taking valproate during spermatogenesis, challenging earlier safety concerns and current UK restrictions on valproate use in men. As previously reported by Medscape Medical News , the decision to restrict the drug in women and in men younger than 55 years was made in January 2024, after the UK Medicines and Healthcare products Regulatory Agency issued new guidance on the drug's use. 'Paternal exposure to antiseizure medication in association with conception is unlikely to pose any major risk for the offspring,' the investigators led by Jakob Christensen, DrMedSci, consultant neurologist at Aarhus University Hospital and professor at Aarhus University, Aarhus, Denmark, noted. The study was published online on May 22 in JAMA Network Open . Unnecessary Precaution? In the US and Europe, there is strong guidance about avoiding valproate in pregnant women and women of childbearing age due to an elevated risk for birth defects and other developmental problems. In January 2024, the European Medicines Agency's (EMA's) safety committee (Pharmacovigilance Risk Assessment Committee [PRAC]) expanded precautionary measures on valproate use to men considering fatherhood. The advisory was fueled largely by an observational study by the contract research organization IQVIA. The study showed that about 5 out of 100 children had an NDD when born to fathers taking valproate during the 3 months before conception compared with about 3 out of 100 when born to fathers treated with lamotrigine or levetiracetam. Last summer, Christensen and colleagues were unable to replicate the IQVIA results in a study using a subset of the same IQVIA data. However, at the time, only limited information about the IQVIA study was publicly available. Once additional information from the IQVIA study became available, the researchers tried again to replicate the findings, aligning their methods more closely with the IQVIA study. Despite using the same methodology and incorporating additional data, they were still unable to replicate the IQVIA findings. Their conclusion remained unchanged — there was no statistically significant increased risk for NDDs. Specifically, among 961 children exposed to paternal valproate monotherapy and 1401 exposed to lamotrigine or levetiracetam, there was no significant increase in risk for NDDs (adjusted hazard ratio [aHR], 1.02; 95% CI, 0.67-1.54). 'This finding remained robust across analyses of specific NDDs, analyses of valproate dose, analyses accounting for time trends, analyses allowing for polytherapy, analyses expanding the definition of NDDs, analyses restricted to fathers with epilepsy, and analyses with a restricted exposure window,' Christensen and colleagues reported. Restricting analyses to fathers with epilepsy of unknown cause yielded a higher risk (aHR, 2.48; 95% CI, 1.13-5.44), but this association was no longer significant in analyses matched on birth year (aHR, 2.33; 95% CI, 1.00-5.44). Additional sensitivity analyses (restricting exposure window, excluding children with epilepsy or maternal epilepsy, and accounting for polytherapy) consistently showed no elevated risk for NDDs associated with paternal valproate exposure. 'We've examined this issue from many angles and still find no evidence supporting the concern behind EMA's recommendations,' Christensen said in a news release. Will the EMA Reconsider? Reached for comment, Aatif Husain, MD, epileptologist, neurologist, and sleep medicine specialist at DukeHealth, Durham, North Carolina, said, 'There seems to be a fair amount of literature' suggesting no increased risk for NDDs in children whose fathers use valproate. 'A recent systematic review that included 10 other studies came to this same conclusion,' said Husain, who wasn't involved in the Danish study. Taken together, the data 'would probably move EMA to relook at their guidance to see if it needs to be modified,' he said. Medscape Medical News reached out to the EMA press office for comment and received the following response. 'As with every medicine authorized in the EU, EMA continues monitoring and supervising the safety of these medicines. This includes monitoring information from various sources, such as spontaneous reports, clinical studies, scientific literature, and management of safety signals, which consists of a set of activities to determine whether there are new risks associated with an active substance or a medicine or whether known risks have changed. Should there be any updates, EMA will communicate them via the PRAC Highlights.' Husain told Medscape Medical News that neither the FDA nor the American Epilepsy Society has issued guidance on valproate use in men 'because the data has not been strong enough.'

The 9th Belt and Road Teenager Maker Camp & Teacher Workshop to Launch Soon
The 9th Belt and Road Teenager Maker Camp & Teacher Workshop to Launch Soon

Associated Press

timea day ago

  • Associated Press

The 9th Belt and Road Teenager Maker Camp & Teacher Workshop to Launch Soon

Sichuan, China, June 9, 2025 -- From June 10 to 15, the 9th Belt and Road Teenager Maker Camp & Teacher Workshop will take place in Sichuan, China. Jointly hosted by the China Association for Science and Technology, the Ministry of Science and Technology of the People's Republic of China, and the People's Government of Sichuan Province, the event is featured as part of the 2nd Belt and Road Conference on Science and Technology Exchange. It aims to build a cross-border platform of science, technology, and culture for the youth. Under the theme, 'Engineering Builds a Better Future,' the event adopts a hybrid 'online-offline' model, featuring 'one main camp + five regional sub-camps + one online platform.' The main camp in Sichuan will focus on two key areas: 'Low-Carbon City Development' and 'Smart Rail Transit, for the Future.' Participants will visit innovation hubs,including laboratories at Sichuan University and the National Experimental Teaching Demonstration Center for Transportation at Southwest Jiaotong University. They will engage in hands-on projects involving maglev trains and environmental technologies, while also experiencing intangible cultural heritage, including Shu embroidery and shadow puppetry. The itinerary includes visits to the Dujiangyan Irrigation System and Chengdu Research Base of Giant Panda Breeding, fostering international understanding through a blend of scientific exploration and cultural immersion. Sub-camps will take place in Shaanxi, Ningxia, Xinjiang, Guangxi, Yunnan, and other regions. Meanwhile, young participants from around the world can collaborate on cross-border learning and innovation projects through the 'cloud classroom' hosted on the Belt and Road Virtual Science Center's online platform. This year's event will also feature the launch of the 'Youth Imagination Education Initiative,' inviting science fiction works published from Belt and Road countries to promote the development of a shared sci-fi education community among teenagers across these member countries. Contact Info: Name: Jack Huang Email: Send Email Organization: China Central Television Website: Release ID: 89161894 In the event of any inaccuracies, problems, or queries arising from the content shared in this press release, we encourage you to notify us immediately at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our diligent team will be readily available to respond and take swift action within 8 hours to rectify any identified issues or assist with removal requests. Ensuring the provision of high-quality and precise information is paramount to us.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store